Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
?

?

0.870%
0.1
0.870%
-
 
07:36 / Stuttgart Stock Exchange WKN: A2DG49 / Name: KalVista / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Carbylan Therapeutics Inc Stock

The Carbylan Therapeutics Inc stock is trending slightly upwards today, with an increase of €0.10 (0.870%) compared to yesterday's price.
So far the community has only identified positive things for Carbylan Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Carbylan Therapeutics Inc in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Carbylan Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Carbylan Therapeutics Inc 0.870% 23.656% 12.745% 28.492% 43.750% 132.746% -27.673%
Pharma Mar S.A. 0.070% 7.194% -6.405% 0.736% -4.626% 16.631% -24.143%
Clinuvel Pharmaceuticals 0.650% 1.075% -5.855% -24.754% -15.608% -51.022% -51.604%
Optibiotix Health plc - -0.592% -16.000% -45.806% -58.000% -62.500% -85.953%

News

KalVista Posts 154% Expense Jump in Q1
KalVista Posts 154% Expense Jump in Q1

KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept